Viewing Study NCT06750094


Ignite Creation Date: 2025-12-25 @ 1:34 AM
Ignite Modification Date: 2026-01-06 @ 7:59 AM
Study NCT ID: NCT06750094
Status: RECRUITING
Last Update Posted: 2025-12-19
First Post: 2024-12-20
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Sponsor: Janssen Research & Development, LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module